Reduced raltegravir clearance in HIV-infected liver transplant recipients: An unexpected interaction with immunosuppressive therapy?

Dario Cattaneo, M. Puoti, Salvatore Sollima, C. Moioli, Caterina Uberti Foppa, S. Baldelli, Emilio Giuseppe Ignazio Clementi, Cristina Gervasoni

Research output: Contribution to journalArticle


Objectives: Liver transplantation (LTx) is considered a safe procedure in selected HIV-infected patients. In this clinical setting raltegravir is the antiretroviral of choice due to its optimal tolerability and its negligible interactions with immunosuppressive drugs. We aimed at providing data on the pharmacokinetics of raltegravir in LTx recipients, on which the available information is inconclusive. Methods: In this retrospective multicentre study we characterized the pharmacokinetics of raltegravir in a consecutive series of HIV-infected LTx recipients referred to our laboratory for therapeutic drug monitoring (TDM) and compared the obtained profiles with those collected from a control group of HIV-infected patients. Results: Seventeen HIV-infected LTx patients were considered. LTx recipients had significantly higher raltegravir AUC0-12 compared with the control group of HIV-infected patients [14314 (11627-19998) versus 8795 (5218- 12954) ng.h/mL; P

Original languageEnglish
Article numberdkv466
Pages (from-to)1341-1345
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Issue number5
Publication statusPublished - May 1 2016


ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this